Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study

被引:65
作者
Broeks, Annegien
Braaf, Linde M.
Huseinovic, Angelina
Nooijen, Anke
Urbanus, Jos
Hogervorst, Frans B. L.
Schmidt, Marjanka K.
Klijn, Jan G. M.
Russell, Nicola S.
Van Leeuwen, Flora E.
Van 't Veer, Laura J.
机构
[1] Netherlands Canc Inst, Div Expt Therapy, NL-1066 CX Amsterdam, Netherlands
[2] Netherlands Canc Inst, Dept Pathol, NL-1066 CX Amsterdam, Netherlands
[3] Netherlands Canc Inst, Dept Epidemiol, NL-1066 CX Amsterdam, Netherlands
[4] Netherlands Canc Inst, Dept Radiotherapy, NL-1066 CX Amsterdam, Netherlands
[5] Dr Daniel Den Hoed Canc Ctr, Dept Med Oncol, NL-3075 EA Rotterdam, Netherlands
来源
BREAST CANCER RESEARCH | 2007年 / 9卷 / 02期
关键词
D O I
10.1186/bcr1668
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction Radiation exposure at a young age is one of the strongest risk factors for breast cancer. Germline mutations in genes involved in the DNA-damage repair pathway (DDRP) may render women more susceptible to radiation-induced breast cancer. Methods We evaluated the contribution of germline mutations in the DDRP genes BRCA1, BRCA2, CHEK2 and ATM to the risk of radiation-induced contralateral breast cancer (CBC). The germline mutation frequency was assessed, in a case-only study, in women who developed a CBC after they had a first breast cancer diagnosed before the age of 50 years, and who were (n = 169) or were not ( n = 78) treated with radiotherapy for their first breast tumour. Results We identified 27 BRCA1, 5 BRCA2, 15 CHEK2 and 4 truncating ATM germline mutation carriers among all CBC patients tested (21%). The mutation frequency was 24.3% among CBC patients with a history of radiotherapy, and 12.8% among patients not irradiated for the first breast tumour ( odds ratio 2.18 (95% confidence interval 1.03 to 4.62); p = 0.043). The association between DDRP germline mutation carriers and risk of radiation-induced CBC seemed to be strongest in women who developed their second primary breast tumour at least 5 years after radiotherapy. Those patients had an odds ratio of 2.51 ( 95% confidence interval 1.03 to 6.10; p = 0.049) of developing radiation-induced breast cancer, in comparison with non-carriers. Conclusion This study shows that carriers of germline mutations in a DDRP gene have an increased risk of developing ( contralateral) breast cancer after radiotherapy; that is, over and above the risk associated with their carrier status. The increased risk indicates that knowledge of germline status of these DDRP genes at the time of breast cancer diagnosis may have important implications for the choice of treatment.
引用
收藏
页数:9
相关论文
共 46 条
[1]   Effect of chest x-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the International BRCA1/2 Carrier Cohort Study:: A report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group [J].
Andrieu, Nadine ;
Easton, Douglas F. ;
Chang-Claude, Jenny ;
Rookus, Matti A. ;
Brohet, Richard ;
Cardis, Elisabeth ;
Antoniou, Antonis C. ;
Wagner, Teresa ;
Simard, Jacques ;
Evans, Gareth ;
Peock, Susan ;
Fricker, Jean-Pierre ;
Nogues, Catherine ;
Van't Veer, Laura ;
Van Leeuwen, Flora E. ;
Goldgar, David E. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (21) :3361-3366
[2]  
Angèle S, 2003, CANCER RES, V63, P8717
[3]  
[Anonymous], 1989, Molecular Cloning
[4]  
[Anonymous], CANC EPIDEMIOLOGY PR
[5]   Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:: A combined analysis of 22 studies [J].
Antoniou, A ;
Pharoah, PDP ;
Narod, S ;
Risch, HA ;
Eyfjord, JE ;
Hopper, JL ;
Loman, N ;
Olsson, H ;
Johannsson, O ;
Borg, Å ;
Pasini, B ;
Radice, P ;
Manoukian, S ;
Eccles, DM ;
Tang, N ;
Olah, E ;
Anton-Culver, H ;
Warner, E ;
Lubinski, J ;
Gronwald, J ;
Gorski, B ;
Tulinius, H ;
Thorlacius, S ;
Eerola, H ;
Nevanlinna, H ;
Syrjäkoski, K ;
Kallioniemi, OP ;
Thompson, D ;
Evans, C ;
Peto, J ;
Lalloo, F ;
Evans, DG ;
Easton, DF .
AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 72 (05) :1117-1130
[6]  
Bennett LM, 1999, MOL CARCINOGEN, V26, P143, DOI 10.1002/(SICI)1098-2744(199911)26:3<143::AID-MC2>3.0.CO
[7]  
2-S
[8]   The CHEK2*1100de/C allelic variant and risk of breast cancer:: Screening results from the breast cancer family registry [J].
Bernstein, JL ;
Teraoka, SN ;
John, EM ;
Andrulis, IL ;
Knight, JA ;
Lapinski, R ;
Olson, ER ;
Wolitzer, AL ;
Seminara, D ;
Whittemore, AS ;
Concannon, P .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2006, 15 (02) :348-352
[9]   Study design: Evaluating gene-environment interactions in the etiology of breast cancer - the WECARE study [J].
Bernstein, JL ;
Langholz, B ;
Haile, RW ;
Bernstein, L ;
Thomas, DC ;
Stovall, M ;
Malone, KE ;
Lynch, CF ;
Olsen, JH ;
Anton-Culver, H ;
Shore, RE ;
Boice, JD ;
Berkowitz, GS ;
Gatti, RA ;
Teitelbaum, SL ;
Smith, SA ;
Rosenstein, BS ;
Borresen-Dale, AL ;
Concannon, P .
BREAST CANCER RESEARCH, 2004, 6 (03) :R199-R214
[10]   CANCER IN THE CONTRALATERAL BREAST AFTER RADIOTHERAPY FOR BREAST-CANCER [J].
BOICE, JD ;
HARVEY, EB ;
BLETTNER, M ;
STOVALL, M ;
FLANNERY, JT .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (12) :781-785